Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as QTORIN 3.9% rapamycin anhydrous gel, QTORIN 3.9% rapamycin anhydrous
QTORIN rapamycin · 3 trials · 3 indications
A multi-point scale with higher values indicating improvement.
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | - |
| Vehicle | PLACEBO_COMPARATOR | - |
| Single-arm, open-label | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| QTORIN 3.9% Rapamycin Anhydrous Gel | DRUG | QTORIN 3.9% Rapamycin Anhydrous Gel |
| Vehicle | DRUG | Matching vehicle (QTORIN anyhydrous gel) |
Key Inclusion Criteria: * Participant must be at least 3 years of age at time of consent/assent * Participant must have a clinically confirmed superficial/cutaneous microcystic lymphatic malformation Key Exclusion Criteria: * Participants who have vascular malformations that interfere with evalua...
QTORIN rapamycin is an investigational topical small molecule developed by Palvella Therapeutics for dermatologic conditions. It is formulated as a 3.9% rapamycin anhydrous gel and is being studied in cutaneous venous malformations, microcystic lymphatic malformation, and pachyonychia congenita. It is not approved and remains in clinical development.
QTORIN rapamycin is being developed to treat cutaneous venous malformations, microcystic lymphatic malformation, and pachyonychia congenita. These are dermatologic conditions involving vascular and lymphatic malformations and a rare keratinization disorder. The drug is investigational and has not been approved for any indication.
QTORIN rapamycin is developed by Palvella Therapeutics, Inc., which trades under the ticker PVLA. The company is advancing the topical rapamycin gel across vascular malformation and pachyonychia congenita programs.
QTORIN rapamycin is in Phase 2 and Phase 3 clinical development depending on the indication. A Phase 2 study is evaluating it in cutaneous venous malformations, while Phase 3 studies have been conducted in microcystic lymphatic malformation and pachyonychia congenita. It is investigational and not FDA approved.
QTORIN rapamycin has been studied in NCT06653842, a Phase 2 baseline-controlled trial in cutaneous venous malformations; NCT06239480, the Phase 3 SELVA study in microcystic lymphatic malformation; and NCT05180708, a completed Phase 3 randomized, double-blind, vehicle-controlled study in pachyonychia congenita.
Yes. QTORIN rapamycin is also known as QTORIN 3.9% rapamycin anhydrous gel, QTORIN 3.9% rapamycin anhydrous, and QTORIN 3.9% Rapamycin Anhydrous Gel. These names refer to the same investigational topical formulation developed by Palvella Therapeutics.